IL-11 Luciferase Reporter Assay for Faster Specific Bioactivity Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing method for testing the biological activity of human interleukin-11 (IL-11) is time-consuming and requires the use of toxic reagents, lacking specificity due to the similarity in biological activities with IL-6, necessitating the use of anti-IL-6 monoclonal antibodies.
Innovation Solution
A method utilizing luciferase reporter genes and cell strains is developed, involving the construction of pPR(EXP)-STAT3 plasmids, transfection of HEK293T cells, and screening for stable cell lines to test IL-11 activity through luciferase activity, eliminating the need for toxic reagents and reducing the testing time to 24-28 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the cell proliferation inhibition method using B9-11 cells is used to test IL-11 biological activity, then the testing can be performed according to Chinese Pharmacopoeia standards, but the testing time is extended to 48-56 hours and requires toxic MTT reagent
Solution Approach 1:
The patent replaces the traditional cell proliferation inhibition method (which relies on MTT reagent and cell growth measurement over 48-56 hours) with a luciferase reporter gene system. This substitution enables real-time detection of IL-11 biological activity through luminescence signals, reducing testing time to 24-28 hours while eliminating the need for toxic reagents.
Solution Approach 2:
The patent changes the detection parameter from cell proliferation rate (measured by MTT) to luciferase activity (measured by luminescence intensity). This parameter change allows for faster readout and eliminates the long incubation period required for cell proliferation assays, while maintaining reliability through the specific STAT3 promoter-driven luciferase expression.
2Reliability
If the cell proliferation inhibition method using B9-11 cells is used to test IL-11 biological activity, then the testing can be performed according to Chinese Pharmacopoeia standards, but toxic MTT reagent is required which affects safety
Solution Approach 1:
The patent substitutes the toxic MTT reagent-based detection system with a luciferase-based luminescence detection system. This replacement eliminates exposure to harmful chemicals while providing a safer, more environmentally friendly assay that maintains analytical reliability through the specific interaction between IL-11 and the STAT3 promoter-driven luciferase expression.
Solution Approach 2:
The patent employs a reporter gene system that provides rapid, single-use detection without requiring expensive or toxic reagents. The luciferase assay uses inexpensive substrates and reagents that can be disposed of after a single measurement, eliminating the need for costly and hazardous MTT reagent while maintaining testing reliability.
3Measurement precision
If anti-IL-6 monoclonal antibody is used to neutralize IL-6 activity in each sample test, then the specificity of IL-11 testing is improved, but the device complexity and operation complexity increase
Solution Approach 1:
The patent extracts and isolates the specific signaling pathway response to IL-11 by using a STAT3 promoter-driven luciferase reporter system. This extraction of the specific biological response mechanism eliminates the need for additional neutralizing antibodies, as the system inherently responds specifically to IL-11 through the IL-11 receptor-STAT3 signaling axis, thereby simplifying the overall testing procedure while maintaining high specificity.
4Measurement precision
If anti-IL-6 monoclonal antibody is used to neutralize IL-6 activity in each sample test, then the specificity of IL-11 testing is improved, but the operation time is extended
Solution Approach 1:
The patent extracts the specific IL-11 response mechanism through the STAT3 promoter-luciferase system, which naturally responds to IL-11 signaling without requiring additional neutralization steps. This extraction of the specific biological response eliminates the time-consuming antibody neutralization procedure while maintaining specificity, reducing total testing time from 48-56 hours to 24-28 hours.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a rapid, specific, and sensitive test for IL-11 activity, improving efficiency and safety by avoiding toxic reagents and shortening the experimental time while maintaining high accuracy and reliability.
Implementation Method 1
testing the biological activity of human interleukin-11 by determining luciferase activity
Data Source
AI summary
The present disclosure provides a method for rapidly testing biological activity of human interleukin-11 on the basis of luciferase reporter genes, and a construction method and application of cell strains. The method includes the following steps: 1) constructing cell strains based on luciferase reporter genes; and 2) preparing a sample to be tested into a gradient dilution solution, adding same into a culture solution, then, adding the culture solution into a culture medium containing the cell strains, and after co-incubation, testing the biological activity of human interleukin-11 by determining luciferase activity. The present disclosure successfully constructs a new method for testing the biological activity of interleukin-11 (IL-11). Experimental time is shortened from 48-56 h to 24-28 h by the constructed RGA method, and working efficiency is obviously improved, such that the time cost is saved.